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INTRODUCTION
The American Society for Blood and Marrow Transplantation (ASBMT) has begun the development of evidence-based
reviews and position statements on the effectiveness of autologous and allogeneic hematopoietic stem cell transplantation for
speciﬁc diseases. This effort is part of ASBMT’s Managed Care Initiative to achieve broader coverage from payers for estab-
lished indications for blood and marrow transplantation.
The ASBMT Policy Statement Regarding the Methodology of Evidence-Based Reviews in Evaluating the Role of Blood
and Marrow Transplantation in the Treatment of Selected Diseases has been developed by the project’s Steering Committee
and is presented below.
THE NEED FOR EVIDENCE-BASED REVIEWS
Many patients continue to be denied needed autologous and allogeneic stem cell transplants.  Although medically and
clinically accepted for certain disease states, blood and marrow transplantation continues to be viewed as investigational or
experimental by some third-party payers. Managed care organizations in particular are frequently reluctant or unwilling to
reimburse medical procedures that they perceive to be novel, investigational, or more expensive than conventional therapies.
To address these concerns, ASBMT, together with patient advocacy organizations and other interested entities, is devel-
oping guidelines based on authoritative information about blood and marrow transplantation as an effective treatment
modality.  The strategy is 3-fold:
• Bring together a coalition of stakeholders to address the issues of third-party reimbursement for blood and marrow
transplantation;
• Document for speciﬁc diseases the efﬁcacy of blood and marrow transplantation;
• Advocate on behalf of bone marrow transplantation (BMT) patients to those who decide or inﬂuence treatment reim-
bursement decisions.
The challenge centers on awareness and communication. Treatment beneﬁts that may be obvious to clinicians and inves-
tigators in the ﬁeld of hematopoietic stem cell therapy may, in fact, not be so obvious to others responsible for health care
policies and administration—individuals who make or inﬂuence decisions in managed care, indemnity insurance, employee
health beneﬁts programs, legislation, regulations, and the media.  The objective is to raise awareness and enhance communi-
cation, using the platform of evidence-based reviews and position statements.
THE PROCESS FOR DEVELOPING THE REVIEWS
Responsibility for the development of the evidence-based reviews has been assigned to an ASBMT Board of
Directors–appointed Steering Committee, chaired by Roy B. Jones, MD, University of Colorado Health Sciences Center,
Denver, CO. Each installment in a series of disease-speciﬁc reviews, sequentially prepared and released, will have its own
expert panel that includes representatives from a broad spectrum of cancer management, third-party payers, and patients.
The ﬁrst review, already underway, will address diffuse large B-cell non-Hodgkin's lymphoma.
To guide its own activities and that of the expert panels, the Steering Committee has developed this Policy Statement
Regarding the Methodology of Evidence-Based Reviews in Evaluating the Role of Blood and Marrow Transplantation in the
Treatment of Selected Diseases. The statement denotes principles and criteria for evidence-based reviews and methods for
categorizing and reporting medical evidence.
The following statement has been submitted to and accepted by the ASBMT Executive Committee.
Evidence-Based Reviews and the Role of Blood and
Marrow Transplantation in the Treatment of 
Selected Diseases: An ASBMT Policy Statement
Biology of Blood and Marrow Transplantation 6:523 (2000)
© 2000 American Society for Blood and Marrow Transplantation ASBMT
524
Evidence-based medicine depends on critical review and
analysis of published studies in the medical literature.
Reported clinical outcomes must be evaluated and sorted
according to an evidence hierarchy that is determined by the
validity and reliability of the study methodologies used [1-3].
AGENDA FOR EVIDENCE-BASED REVIEWS
The agenda for an evidence-based review of a specific 
medical treatment should include the following 9 elements [4-7]:
• Statement of purpose for the review;
• Ιdentiﬁcation of criteria for the literature search;
• Statement of principles for inclusion—or exclusion—
of individual studies;
• Assessment of the validity and reliability of individual
studies;
• Collation of the study results, including notation of
any data limitations or inconsistencies;
• Weighting of study results, based on quantitative and
qualitative criteria;
• Summarizing the ﬁndings;
• Conclusions regarding the value of the treatment;
• Recommendations for additional areas of research.
PRINCIPLES OF EVIDENCE ASSESSMENT
Each published study must be systematically and consis-
tently evaluated according to its quality and strength [2,4-
6,8]. Quality factors include (1) validity and reliability of
study methodology, (2) patient selection, (3) intended and
unintended biases, (4) treatment outcomes, and (5) therapy
limitations. A system for grading the quality of evidence is
presented in Table 1 [9].
Strength factors include (1) magnitude of the treatment
effects, (2) safety (ie, beneﬁts versus risks), and (3) econom-
ics (ie, benefits versus costs). A system for grading the
strength of evidence is presented in Table 2 [10].
END POINT ASSESSMENT
Traditionally, overall survival and disease-free survival
have been the end points used to assess new medical interven-
tions. More recently, however, quality-of-life factors have
gained importance. Valid end points other than overall and
disease-free survival may include (1) disability, (2) return to
work or school, (3) comorbid events, and (4) cost-effectiveness
for the patient, the payer, and society. Although quality-of-life
data frequently are not reported in clinical studies, these vari-
ables should be considered when data are available.
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META-ANALYSIS
The medical literature evaluation should collate and
interpret all of the published studies of the pertinent treat-
ment. A meta-analysis of individual patient data is preferred
because it is the least biased and most reliable interpretation
of all published and unpublished clinical trials performed
using the selected therapies [11]. If this is not feasible, a
meta-analysis of the literature based on information
extracted from published studies is acceptable, as long as the
biases associated with this type of analysis are acknowledged.
Tests of homogeneity between studies can be performed
to determine degrees of variation. Sensitivity analyses can
compare how various study criteria affect scientific out-
comes. Studies judged to be of poor quality or weak method-
ology should be identified explicitly as such and discarded
from the analysis.
CONCLUSIONS AND RECOMMENDATIONS
After all of the evidence has been critically reviewed and
analyzed, a decision is reached on the relative value and role
of the treatment. Recommendations are offered based on the
strength of the evidence, the heterogeneity of the studies,
and the magnitude and precision of the treatment effect. If
the evidence is inadequate to support a recommendation,
such information must be reported. A system for categoriz-
ing treatment recommendations is presented in Table 3. 
In addition to developing conclusions about the treat-
ments, an evidence-based review should provide recommen-
dations for future research. Proposals to close gaps in cur-
rent knowledge may address new research questions,
alternative study methodologies, and priorities for new
research initiatives. An interval between this and the next
evidence-based review should be suggested, taking into
account studies currently underway and those that are posed.
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Table 2. Grading the Strength of the Evidence
Grade Definition
1 Experimental therapy significantly better (P < .05)
2 Trend in favor of experimental therapy (P > .05)
3 No apparent statistical effect
4 Trend favoring control group (P > .05)
5 Control group significantly better (P < .05)
Reprinted with permission [10].
Table 3. Classiﬁcations for Treatment Recommendations 
Classification Definition
1 Effective treatment
2 Marginally effective treatment
3 Not an effective treatment (no statistical or
clinical difference between therapies)
4 Inadequately evaluated treatment and 
recommended for comparative study
5 Inadequately evaluated treatment but not 
recommended for comparative study
Table 1. Grading the Quality of Evidence
Grade Definition
1 Evidence obtained from at least 1 properly 
randomized controlled trial
2-1 Evidence obtained from well-designated controlled
trials without randomization
2-2 Evidence obtained from well-designated cohort or 
case-controlled analytic studies, preferably from 
more than one center or research group
2-3 Evidence obtained from multiple timed series 
with or without the intervention, or from 
dramatic results in uncontrolled experiments
3 Opinions of respected authorities based on clinical 
experience, descriptive studies, or reports of 
expert committees
4 Evidence that is inadequate because of problems 
with methodology (eg, sample size, length or 
comprehensiveness of follow-up, or conflict 
in evidence)
Reprinted with permission [9].
